Labcorp Raises Guidance as Revenue Hits $3.8 Billion
The company reported 7% third-quarter growth and announced three acquisitions in specialty testing.
Updated on Nov. 13, 2026 in Healthcare

Labcorp reported third-quarter 2026 revenue of $3.8 billion, up 7%, on October 28, 2026, and raised its full-year guidance. The company also announced agreements to acquire assets from BioReference, Myriad Genetics' prenatal business, and Millennium Health.
Why it matters
Labcorp's specialty testing business grew about three times faster than the broader diagnostics market, a trend the company says supports its core laboratory business. Proposed Medicare fee schedule changes under PAMA could reduce reimbursement across hundreds of tests starting in 2027.
Labcorp's third-quarter 2026 revenue reached $3.8 billion, a 7% increase, with specialty testing expanding about three times faster than the broader diagnostics market. The company has not disclosed the financial terms of its three announced acquisitions, and the full-year guidance figures were not detailed in the source material.
The players
Labcorp
Labcorp is a major U.S. clinical laboratory company that operates two segments and provides diagnostic testing services across healthcare providers and patients.
The details
Labcorp reported its results on its October 28, 2026 earnings call and said the quarter marked the sixth consecutive quarter of margin progression across the enterprise. The company is pursuing growth through tuck-in acquisitions it expects to be accretive to adjusted earnings per share in year one, and it is supporting margins through its Launchpad enterprise cost savings program.
Timeline
- October 28, 2026: Labcorp holds its third-quarter 2026 earnings call and reports results.
- 2027: Proposed PAMA Medicare reimbursement cuts are expected to take effect.
Market Landscape
Labcorp's expansion through acquisitions of BioReference, Myriad Genetics' prenatal business, and Millennium Health reflects consolidation in specialty diagnostics. Proposed changes under the Protecting Access to Medicare Act (PAMA) fee schedule are a central pressure pushing laboratory operators to grow beyond routine testing.
Patients who rely on Medicare-covered lab tests could see changes in how and where those tests are ordered as reimbursement rates shift in 2027. The impact on individual test prices and availability has not been specified in the source material.
The takeaway
Lab companies are increasingly relying on specialty testing and acquisitions to offset pressure on routine reimbursement rates. Readers tracking healthcare costs should watch how proposed PAMA changes are finalized for 2027.
Further reading
For broader context on hospital and lab-sector spending, explore Healthcare coverage on Wisevoter.
Source note: This article includes information reported by The Motley Fool.





